Thoratec calls off $110M sale of ITC division

Thoratec Corporation, a maker of device-based mechanical circulatory support therapies, announced that it has canceled the previously-announced $110 million deal to sell its International Technidyne Corporation (ITC) division to Danaher Corporation. The two sides couldn't agree on the status of ITC's quality system and regulatory filings. Additionally, the FDA denied approval of ITC's ProTime InRhythm, causing Thoratec and Danaher to disagree on whether closing conditions of the deal were met.

Thoratec says ITC will focus on gaining 510(k) clearance for InRhythm. The company plans to file a new submission for the device by the end of 2010. Thoratec's board of directors still expects it will be able to sell ITC off in the next twelve months.

- read the Thoratec release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.